Clinical Characteristics of Patients with Different N-Terminal Probrain Natriuretic Peptide Levels after Hematopoietic Stem Cell Transplantation

Abstract EN

Heart failure (HF) is not uncommon among patients with hematologic malignancies (HM) undergoing hematopoietic stem cell transplantation (HSCT) and is associated with an increased mortality.

Among HSCT patients without signs or symptoms of HF, groups with elevated and normal N-terminal probrain natriuretic peptide (NT-proBNP) levels have been poorly characterized in previous literature.

Herein, we reviewed consecutive admissions for HM undergoing HSCT (n=301).

Based on NT-proBNP levels and clinical signs or symptoms of HF at follow-up (one month after HSCT), patients were grouped into ENPH (elevated NT‐proBNP>125 pg/mL, presence of HF symptoms or signs), ENAH (elevated NT‐proBNP>125 pg/mL, absence of HF symptoms or signs), and NN (normal NT‐proBNP<125 pg/mL).

ENPH, ENAH, and NN were observed in 22.9%, 54.5%, and 22.6% of patients, respectively.

ENPH patients had a significantly higher baseline NT-proBNP level, followed by the ENAH and NN groups, respectively (P<0.001).

Frequencies of HLA partially matched related donors, stem cell source (bone marrow+peripheral blood), and utilization of graft-versus-host disease prophylaxis regimens (ciclosporin+methotrexate+antithymocyte globulin±mycophenolate mofetil) were also the highest in the ENPH group, followed by ENAH and NN groups, respectively (all P<0.05).

Uric acid and hemoglobin levels, transplant type, and cyclophosphamide-based conditioning regimens utilized were similar between the ENAH and ENPH groups.

We found that ENPH and ENAH are commonly observed in HM hospitalized for HSCT.

Serum NT-proBNP levels may allow for earlier identification of HSCT patients at high risk of developing cardiac dysfunction.